BDAR
gdpr

The challenges of rational medication use during the pandemic were discussed at a medical conference

Date

2021 12 27

Rating
1
1310_06fb7a3240ede2ac8e150440f25d1771.jpg

Lithuanian society of clinical pharmacology, Šiauliai territorial health insurance fund (THIF) and Šiauliai medicines committee hosted a practical scientific conference to discuss ‘The challenges of rational use of reimbursed medication during the pandemic’, which took place at Šiauliai state hospital. The conference was organised in order to promote rational prescription and use of medicines.

The conference, dedicated to doctors, working in all fields, pharmacists, nurses and health care managers, featured presentations, delivered by Professor Romaldas Mačiulaitis of the Lithuanian University of Health Sciences (LSMU), Irma Medžiaušaitė, Advisor of the Pharmaceuticals Reimbursement Division of the National Health Insurance Fund (NHIF) under the Ministry of Health, Dalia Ozolienė, Head of Control Division of Šiauliai THIF, and Darius Dicevičius, Chief Specialist of the same division.

The conference was opened by Irma Medžiaušaitė, Advisor of the NHIF Pharmaceuticals Reimbursement Division, who delivered a presentation of the assessment of the indicators of the prescription of reimbursed medicines and the topicalities of reimbursable medicines. Professor Mačiulaitis from LSMU Institute of Physiology and Pharmacology delivered a presentation of the new antibiotics and their rational use.

An overview of the challenges of mental health in the context of the pandemic and ways to deal with them was discussed by Darius Dicevičius.

Dalia Ozolienė, Head of Šiauliai THIF Control Division, discussed changes in the monitoring of blood coagulation in patients taking oral anticoagulants, drawing attention to the fact that the prescription of antithrombotics containing the active substance warfarin is often irrational. This happens, because patients rarely undergo blood clotting tests to determine the dose prior to prescription.

Ozolienė supported her presentation with an analysis of the Medicines Committee, which monitors the effectiveness of patient treatment, indicating an increased number of cases, when patients treated with antithrombotics rarely undergo a blood clotting test or do not have it at all, although it is covered by the Fund.

She reminded that patients that have been prescribed treatment with oral anticoagulants with the active substance warfarin, should undergo a blood clotting test 12 times per year in order to evade complications.

Doctors must prescribe this test at least every 35 years to make a proper assessment of the risk of bleeding or blood clotting (thrombosis) and be able to determine the most suitable dose of medicine.

Professor Mačiulaitis, leading a discussion on ‘What else can be done to rationalise the prescription of medicine’, received interesting insights from Vaiva Krasauskaitė, Kelmė Primary Health Care Centre. She offered to introduce an application that automatically requires blood clotting test results to prescribe antithrombotic drugs in electronic prescriptions. There was also a suggestion of organising training for nurses on the importance of monitoring blood coagulation in patients, treated with indirect oral anticoagulants.

Information of Šiauliai Territorial Health Insurance Fund

The NHIF invites you:

Your questions are welcome by email [email protected] or phone: local (8 5) 232 2222, international +370 5 232 222